Serum miR-146a and miR-155 as Predictors of Virological Control After Entecavir Withdrawal in HBeAg-Positive Chronic Hepatitis B Patients
Turkish Journal of Gastroenterology · 18.03.2025 · 36 (9) · 583-589
DOI: 10.5152/tjg.2025.24685 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Gastroenterology, online erschienen am 18.03.2025. Verfasst von Ming Li Xu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Jiashan County First People's Hospital, Zhejiang, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Guanine, MicroRNAs, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Aims: Distinct virological relapse (VR) has occurred after stopping the use of nucleos(t)ide analogues treatment in patients with chronic hepatitis B (CHB) who are positive for Hepatitis B e antigen (HBeAg). Here, we aimed to identify serum miR-146a and miR- 155 in HBeAg-positive patients with CHB and their relationship with VR after entecavir (ETV) discontinuance. Materials and Methods: Ninety-eight patients with CHB and positive for HBeAg before initiating treatment were analyzed. Virological relapse was defined as 2 consecutive examinations (3 months apart) after treatment discontinuance, both showing an HBV DNA load of more than >2000 IU/mL.
Results
Compared to control, CHB patients were observed with increases in serum miR-146a and miR-155 before starting ETV treatment (P < .001). There were 52 patients (53.1%) experiencing VR at 12 months after discontinuance of ETV treatment. The VR group was demonstrated with increases in serum miR-146a and miR-155 than the non-VR group before starting ETV treatment (P < .001). Whether at the beginning of ETV discontinuance or at 12 months after ETV discontinuance, the VR group was noted with elevations in serum miR-146a and miR-155 than the non-VR group (P < .001).
Conclusion
The findings demonstrated that miR-146a and miR-155 levels in the circulation may be promising assessment tools for identifying sustained-virological responders after ETV discontinuance in CHB patients. Cite this article as: Xu ML, Wang LH. Serum miR-146a and miR-155 as predictors of virological control after entecavir withdrawal in HBeAg-positive chronic hepatitis B Patients. Turk J Gastroenterol. 2025;36(9):583-589.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Jiashan County First People's Hospital, Zhejiang, China.
Zitieren
APA
Xu, M. L., & Wang, L. H. (2025). Serum miR-146a and miR-155 as Predictors of Virological Control After Entecavir Withdrawal in HBeAg-Positive Chronic Hepatitis B Patients. Turkish Journal of Gastroenterology, 36(9), 583-589. https://doi.org/10.5152/tjg.2025.24685
Vancouver
Xu ML, Wang LH. Serum miR-146a and miR-155 as Predictors of Virological Control After Entecavir Withdrawal in HBeAg-Positive Chronic Hepatitis B Patients. Turkish Journal of Gastroenterology. 2025;36(9):583-589. doi:10.5152/tjg.2025.24685
BibTeX
@article{Xu2025,
author = {Xu, Ming Li and Wang, Li Huan},
title = {Serum miR-146a and miR-155 as Predictors of Virological Control After Entecavir Withdrawal in HBeAg-Positive Chronic Hepatitis B Patients},
journal = {Turkish Journal of Gastroenterology},
year = {2025},
volume = {36},
number = {9},
pages = {583--589},
doi = {10.5152/tjg.2025.24685}
}
EUVIMED